Penn spinout Peroxitech raises $25M to advance novel drug to treat acute lung injury

Penn spinout Peroxitech raised $25M to further develop its novel drug candidate, PIP-2. The drug is being designed to protect cells from injury and enable injured cells to recover to near normal levels in patients suffering from acute lung injury.

Peroxitech was launched at PCI in 2016 and now operates out of the Pennovation Center. It was co-founded by Aron Fisher, MD, a professor emeritus in the physiology department at Penn, and Sheldon Feinstein, a former senior research investigator in Penn’s Institute for Environmental Medicine.

Learn more about Peroxitech here.

Skip to content